Chemistry:Simtuzumab
From HandWiki
Short description: Monoclonal antibody
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | LOXL2 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6558H10134N1736O2037S50 |
Molar mass | 147492.33 g·mol−1 |
Simtuzumab (INN; formerly GS 6624) is a humanized monoclonal antibody designed for the treatment of fibrosis.[1] It binds to LOXL2 and acts as an immunomodulator.[2] In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy.[3]
References
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Simtuzumab, American Medical Association.
- ↑ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107". WHO Drug Information 26 (2). https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf.
- ↑ "Gilead Terminates Phase 2 Study of Simtuzumab in Patients With Idiopathic Pulmonary Fibrosis". Gilead. 5 January 2016. http://www.gilead.com/news/press-releases/2016/1/gilead-terminates-phase-2-study-of-simtuzumab-in-patients-with-idiopathic-pulmonary-fibrosis.
![]() | Original source: https://en.wikipedia.org/wiki/Simtuzumab.
Read more |